• Users Online: 271
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Referee Resource Subscribe
Year : 2022  |  Volume : 9  |  Issue : 2  |  Page : 87-96

Role of growth hormone in ART cycles in poor responders: A literature review

1 Department of Obstetrics & Gynaecology, VMMC & Safdarjung Hospital, New Delhi, India
2 Sir Gangaram Hospital, New Delhi, India

Correspondence Address:
Shahida Naghma
C1, B Block, Heritage Green Apartments, Chandan Hula, New Delhi-110074
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/fsr.fsr_17_22

Rights and Permissions

Growth hormone (GH) has been used as an adjunct in the field of female infertility treatment for more than 25 years, although, apart from treating women with GH deficiency its role has not yet been clarified. In the current shift of trend of delaying marriage and childbearing due to career and various other reasons, many women across the world are opting for assisted reproductive techniques (ART). This poses a challenge to the ART experts due to diminished ovarian reserve with advancing age in women. Over the years, the definition of poor responder has also evolved and after the Bologna criteria in 2011 and Poseidon classification, most of the recent studies have used a uniform criterion to define poor responders. The current review recruited studies conducted over the past decade, to ensure uniform criterion for poor responders. After a thorough literature search, 12 studies were selected for review based on the selection criteria a total of 1774 women were included in the intervention group while 3167 women were included in the control group. The review lead us to the conclusion that GH adjuvant therapy in poor responders reduced the dose/duration of gonadotropin used, increased endometrial thickness, improved the number of M II oocytes retrieved, embryos formed, clinical pregnancy rate. However, it has not shown to improve live birth rates in ART cycles. Since there is some evidence that GH adjuvant therapy may benefit young Poor Ovarian Response (POR), more number of large clinical trials need to be performed for further subgroup analysis and benefitting these women seeking ART.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal